Ralinepag vs Treprostinil (Tyvaso)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Ralinepag

Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT03626688 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).

Next expected readout: December 2026 · NCT03683186 (registry estimate)

Reported efficacy

Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)

Result source: NCT03626688

Treprostinil (Tyvaso)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00147199 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).

Next expected readout: December 2027 · NCT07177703 (registry estimate)

Reported efficacy

Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)

Result source: NCT00147199

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Ralinepag: 5 of 5 rows · Treprostinil (Tyvaso): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRalinepagTreprostinil (Tyvaso)
6MWD - Change
absolute change · m
No placebo or comparator arm
-120 m @ 221wka,b,c,d
NCT02279745 · Phase 2 · registry result, not featured evidence
20 m @ 12wka,b,c,d
NCT01268553 · Phase 4 · registry result, not featured evidence
1 other source trial
230 m @ 12wk
NCT00705133 · Phase 2 · registry result, not featured evidence
Dropout rate
44.4%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
15%
NCT02279160 · Phase 2 · registry result, not featured evidence
11.3%f
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
11%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
15.6%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
—
NCT02279160 · Phase 2 · registry result, not featured evidence
—f
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
—
NCT01268553 · Phase 4 · registry result, not featured evidence
4.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
—
NCT00705133 · Phase 2 · registry result, not featured evidence
Serious AEs
46.7%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
10%
NCT02279160 · Phase 2 · registry result, not featured evidence
7.8%f
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 3 more results
0%
NCT01268553 · Phase 4 · registry result, not featured evidence
13.7%
NCT00741819 · Phase 4 · registry result, not featured evidence
0%
NCT00705133 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
headache 64.4%
diarrhoea 37.8%
pain in jaw 33.3%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
headache 77.5% (placebo 28.6%)
nausea 50% (placebo 23.8%)
diarrhoea 47.5% (placebo 14.3%)
NCT02279160 · Phase 2 · registry result, not featured evidence
f
cough 53.9% (placebo 29.2%)
headache 40.9% (placebo 22.5%)
nausea 19.1% (placebo 10.8%)
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 2 more results
cough 74%
headache 43.8%
nausea 30.1%
NCT00741819 · Phase 4 · registry result, not featured evidence
general prostacyclin adverse reaction profile 100%
NCT00705133 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 12 weeks versus 221 weeks.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ralinepag

PVR Change Dyn S Cm5 -52.2 seconds
absolute change · seconds
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Time to First Clinical Worsening Event 13.04 months
time to event · months
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence · converted to months from 56.5 weeks as posted
6MWD - Change 37 m
absolute change · m
No placebo or comparator arm
End of Study (Time of Discontinuation of Study by Sponsor)
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Output 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Index Change L/Min M2 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Pulmonary Arterial Pressure -2 mmHg
absolute change · mmHg
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
PVR 514.6 vs 512 placebo cm @ 22wk
absolute change · cm
NCT02279160 · Phase 2 · registry result, not featured evidence
6MWD - Change 36.2 vs 29.4 placebo m @ 22wk
absolute change · m
NCT02279160 · Phase 2 · registry result, not featured evidence

Treprostinil (Tyvaso)

Six Minute Walk Distance Peak Change 21.6 vs 3 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
21.6 vs 3 placebo m @ 6wk
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening 4 vs 6 placebo count @ 12wk
event rate · count
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Borg Dyspnea 0 vs 0 placebo score @ 12wk
absolute change · score
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Six Minute Walk Distance Trough Change 12.4 vs 0.8 placebo m @ 12wk
absolute change · m
Change from Baseline
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Mlwhf Total -3 vs 0 placebo score @ 12wk
absolute change · score
Global Score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Signs and Symptoms 0 vs 0 placebo score @ 12wk
absolute change · score
NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Clinical Worsening Free 100% (n=6) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
Ventilatory Efficiency Change Slope 1.2 ratio @ 12wk
ratio to baseline · ratio
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
CAMPHOR -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT01268553 · Phase 4 · registry result, not featured evidence
6MWD - Change 16 m @ 12wk
absolute change · m
No placebo or comparator arm
Change from Baseline
NCT00741819 · Phase 4 · registry result, not featured evidence
QOL -2.4 score @ 12wk
absolute change · score
No placebo or comparator arm
Change in Quality of Life Score
NCT00741819 · Phase 4 · registry result, not featured evidence
CAMPHOR -6.4 score @ 12wk
absolute change · score
No placebo or comparator arm
Change in Total Score
NCT00741819 · Phase 4 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Tyvaso)'s landscape